With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...

Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection ...

ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical ...

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.

The M150 is an Advanced Combat Optical Gun sight (ACOG) designed for the US military's M4 and M16 weapon system. It incorporates dual illumination technology using a combination of fiber optics ...

2024. The Company’s common shares will continue to trade on the Nasdaq under the symbol “ACOG”.

不列颠哥伦比亚省温哥华 - 目前市值为249万美元的生物制药公司Alpha Cognition Inc. (NASDAQ:ACOG)与中国医疗系统控股有限公司 (CMS) (867.HK)达成了一项独家协议，授权在除日本以外的多个亚洲地区以及澳大利亚和新西兰使用阿尔茨海默病治疗药物ZUNVEYL。

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...